Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.32 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.32 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1326713 | 0.81 | BCL2A1 (0.46) | BCL2A1SLC6A4GAAHPGDSMN1; SMN2 | |
| SCHEMBL1327427 | 0.81 | BCL2A1 (0.43) | BCL2A1SLC6A4GAAHPGDSMN1; SMN2 | |
| SCHEMBL3582113 | 0.80 | BCL2A1 (0.45) | BCL2A1SLC6A4GAAHPGDSMN1; SMN2 | |
| SCHEMBL493597 | 0.80 | BCL2A1 (0.46) | BCL2A1SLC6A4GAAHPGDSMN1; SMN2 | |
| SCHEMBL493536 | 0.79 | BCL2A1 (0.45) | BCL2A1SLC6A4GAAHPGDSMN1; SMN2 | |
| SCHEMBL644438 | 0.78 | BCL2A1 (0.47) | BCL2A1GAAHPGDSMN1; SMN2AOC3 | |
| SCHEMBL493077 | 0.78 | BCL2A1 (0.44) | BCL2A1SLC6A4GAAHPGDSMN1; SMN2 | |
| SCHEMBL1326749 | 0.77 | BCL2A1 (0.43) | BCL2A1SLC6A4GAAHPGDSMN1; SMN2 | |
| SCHEMBL493821 | 0.77 | BCL2A1 (0.40) | BCL2A1SLC6A4SLC6A2SLC6A3AOC3 | |
| SCHEMBL493769 | 0.75 | BCL2A1 (0.39) | BCL2A1SLC6A4SLC6A2SLC6A3AOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7608619-B2 | Substituted oxazole compounds with analgesic activity | GRUENENTHAL GMBH (DE) | 2009-10-27 | — | — | US | disclosed |
| US-20090069330-A1 | Substituted Oxazole Compounds with Analgesic Activity | GRUENENTHAL GMBH (DE) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069330-A1 | Substituted Oxazole Compounds with Analgesic Activity | OPRK1, OPRD1, OPRM1 | BCL2A1 3829/4885SLC6A4 1057/4885GAA 1591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.